Louis Mauriac
University of Bordeaux
79 Papers
642 Citations
Louis Mauriac is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 39, co-authored 79 publications.
Chat about Author
Papers
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
M Marty,Francesco Cognetti,Dominique Maraninchi,Raymond Snyder,Louis Mauriac,Michèle Tubiana-Hulin,Stephen Chan,David Grimes,Antonio Antón,Anna Lluch,John Kennedy,Kenneth J. O'Byrne,Pierfranco Conte,Michael D. Green,Carol Ward,Karen Mayne,Jean-Marc Extra +16 more
TL;DR: Tastuzumab combined with docetaxel is superior to docetAXel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
1.6K
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Beat Thürlimann,Aparna Keshaviah,Alan S. Coates,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Manuela Rabaglio,Ian E. Smith,Andrew M Wardley,Karen N. Price,Aron Goldhirsch +13 more
TL;DR: In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites.
1.6K
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Bernard Asselain,William E. Barlow,John M. S. Bartlett,Jonas Bergh,Elizabeth Bergsten-Nordström,Judith M Bliss,Francesco Boccardo,Clare Boddington,Jan Bogaerts,Gianni Bonadonna,Rosie Bradley,Etienne Brain,Jeremy P Braybrooke,Philippe Broët,John Bryant,Julie Ann Burrett,David Cameron,Mike Clarke,Alan S. Coates,Robert E. Coleman,Raoul Charles Coombes,C Correa,J. Costantino,Jack Cuzick,David N. Danforth,Nancy E. Davidson,C Davies,Lucy Davies,Angelo Di Leo,David Dodwell,Mitch Dowsett,Fran Duane,Vaughan Evans,Marianne Ewertz,Bernard Fisher,John F. Forbes,Leslie G. Ford,Jean-Claude Gazet,Richard D. Gelber,Lucy Gettins,Luca Gianni,Michael Gnant,Jon Godwin,Aron Goldhirsch,Pamela J. Goodwin,Richard Gray,Daniel F. Hayes,Catherine Hill,James N. Ingle,Reshma Jagsi,Raimund Jakesz,Sam James,Wolfgang Janni,Hui Liu,Z Liu,Caroline Lohrisch,Sibylle Loibl,Liz MacKinnon,Andreas Makris,Eleftherios P. Mamounas,Gurdeep S. Mannu,Miguel Martín,Simone Mathoulin,Louis Mauriac,Paul McGale,Theresa McHugh,Philip Morris,Hirofumi Mukai,Larry Norton,Yasuo Ohashi,Ivo A. Olivotto,Soon Paik,Hongchao Pan,Richard Peto,Martine Piccart,Lori J. Pierce,Philip Poortmans,Trevor J. Powles,Kathy Pritchard,Joseph Ragaz,Vinod Raina,Peter M. Ravdin,Simon Read,Meredith M. Regan,John F.R. Robertson,Emiel J. Th. Rutgers,Suzy Scholl,Dennis J. Slamon,Lidija Sölkner,Joseph A. Sparano,Seth M. Steinberg,Rosemary Sutcliffe,Sandra M. Swain,Carolyn W. Taylor,Andrew Tutt,Pinuccia Valagussa,Cornelis J.H. van de Velde,Jos van der Hage,Giuseppe Viale,Gunter von Minckwitz,Yaochen Wang,Zhe Wang,Xiang Wang,Timothy J. Whelan,Nicholas Wilcken,Eric P. Winer,Norman Wolmark,William C. Wood,Milvia Zambetti,Jo Anne Zujewski +109 more
TL;DR: Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT.
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
Alan S. Coates,Aparna Keshaviah,Beat Thürlimann,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Marco Colleoni,István Láng,Lucia Del Mastro,Ian E. Smith,Jacquie Chirgwin,J.M. Nogaret,Tadeusz Pienkowski,Andrew M Wardley,Erik Jakobsen,Karen N. Price,Aron Goldhirsch +19 more
TL;DR: The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
948
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Henning T. Mouridsen,Anita Giobbie-Hurder,Aron Goldhirsch,Beat Thürlimann,Robert Paridaens,Ian E. Smith,Louis Mauriac,John F. Forbes,Karen N. Price,Meredith M. Regan,Richard D. Gelber,Alan S. Coates +11 more
TL;DR: Among postmenopausal women with endocrine-responsive breast cancer, sequential treatment with letrozole and tamoxifen, as compared with let rozole monotherapy, did not improve disease-free survival.